PAION AG operates as a pharmaceutical company, which engages in the development of drugs to be used in out-patient and hospital-based sedation, anesthesia, and critical care services. The company is headquartered in Aachen, Nordrhein-Westfalen and currently employs 64 full-time employees. The company went IPO on 2005-02-11. The firm's main product is remimazolam, an intravenous ultra-short-acting benzodiazepine sedative and anesthetic. In the human body, remimazolam is metabolized to an inactive metabolite by tissue esterase and not metabolized by cytochrome-dependent hepatic pathways. In addition to that, remimazolam, which is in Phase III clinical development, can be reversed with flumazenil to terminate sedation and anesthesia, if necessary. The product can be used for general anesthesia in Europe and procedural sedation in the United States. The firm operates sites in Aachen, Germany, Cambridge, the United Kingdom, and New Jersey, the United States.
Follow-Up Questions
Qui est le CEO de Paion AG ?
Mr. Gregor Siebert est le Chairman of the Management Board de Paion AG, il a rejoint l'entreprise depuis 2022.
Quelle est la performance du prix de l'action PAIOF ?
Le prix actuel de PAIOF est de $0.01, il a decreased de 0% lors de la dernière journée de trading.
Quels sont les thèmes d'affaires principaux ou les industries de Paion AG ?
Paion AG appartient à l'industrie Biotechnology et le secteur est Health Care
Quelle est la capitalisation boursière de Paion AG ?
La capitalisation boursière actuelle de Paion AG est de $71300
Est-ce que Paion AG est un achat, une vente ou un maintien ?
Selon les analystes de Wall Street, 7 analystes ont établi des notations d'analystes pour Paion AG, y compris 3 achat fort, 5 achat, 1 maintien, 0 vente et 3 vente forte
